Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents

Michael Degtyarev,1 Ann De Mazière,2 Christine Orr,1 Jie Lin,1 Brian B. Lee,1 Janet Y. Tien,1 Wei W. Prior,1 Suzanne van Dijk,2 Hong Wu,3 Daniel C. Gray,1 David P. Davis,1 Howard M. Stern,1 Lesley J. Murray,1 Klaus P. Hofrichter,1 Judith Klumperman,2 Lori S. Friedman,1 and Kui Lin1

Although Akt is known as a survival kinase, inhibitors of the phosphatidylinositol 3-kinase (PI3K)–Akt pathway do not always induce substantial apoptosis. We show that silencing Akt1 alone, or any combination of Akt isoforms, can suppress the growth of tumors established from phosphatase and tensin homologue–null human cancer cells. Although these findings indicate that Akt is essential for tumor maintenance, most tumors eventually rebound. Akt knockdown or inactivation with small molecule inhibitors did not induce significant apoptosis but rather markedly increased autophagy. Further treatment with the lysosomotropic agent chloroquine caused accumulation of abnormal autophagolysosomes and reactive oxygen species, leading to accelerated cell death in vitro and complete tumor remission in vivo. Cell death was also promoted when Akt inhibition was combined with the vacuolar H+-adenosine triphosphatase inhibitor bafilomycin A1 or with cathepsin inhibition. These results suggest that blocking lysosomal degradation can be detrimental to cancer cell survival when autophagy is activated, providing rationale for a new therapeutic approach to enhancing the anticancer efficacy of PI3K–Akt pathway inhibition.

Introduction

Aberrant activation of the class I phosphatidylinositol 3-kinase (PI3K)/Akt pathway has been widely implicated in a variety of cancers, and the three Akt isoforms represent attractive cancer therapeutic targets (Samuels and Ericson, 2006; Stambolic and Woodgett, 2006). Genetic ablations of Akt genes in mice have revealed both distinct and overlapping functions of each isoform in normal physiology (Chen et al., 2001; Cho et al., 2001a, b; Peng et al., 2003; Easton et al., 2005; Tschopp et al., 2005; Yang et al., 2005) and tumor initiation (Chen et al., 2006; Skeen et al., 2006; Ju et al., 2007; Maroulakou et al., 2007). The relative contribution of the Akt isoforms in maintaining human tumor growth remains elusive, however. Human cancers usually co-express two or all three Akt isoforms, and amplification or hyper-activation of each isoform has been documented in different types of cancers (Stahl et al., 2004; Altomare and Testa, 2005). Mounting evidence suggests that Akt isoforms may be differentially regulated depending on the external stimuli and the tissue studied and may regulate distinct aspects of cellular processes in a cell- and tissue-specific manner (Kim et al., 2001; Tanno et al., 2001; Dufour et al., 2004; Irie et al., 2005; Samuel et al., 2005; Yoeli-Lerner et al., 2005).

Akt is well known for its antiapoptotic activity when over-expressed under stress conditions (Amaravadi and Thompson, 2005). However, inhibiting components of the PI3K–Akt pathway...
often does not induce substantial apoptosis without additional proapoptotic insults. This is exemplified in a recent study where a dual PI3K/mammalian target of rapamycin (mTOR) inhibitor that efficiently inhibited phosphorylation of Akt blocked proliferation of glioma xenografts without the induction of apoptosis (Fan et al., 2006). However, the enhanced tumorigenesis stimulated by a constitutively active Akt is linked to its ability to inhibit autophagy but not apoptosis in a recent study (Degenhardt et al., 2006), raising the possibility that autophagy may also be an important mechanism underlying the response to therapeutic agents targeting the PI3K–Akt pathway. Autophagy is a catabolic process characterized by the appearance of autophagic vacuoles (AVs) in the cytoplasm, leading to self-digestion of cytoplasmic organelles and other constituents in the lysosomal compartments. Although autophagy may be capable of ultimate cell killing when allowed to reach its limit, it is also thought to be a temporary survival mechanism under stress conditions, and inhibiting autophagy can either promote or inhibit cell death depending on the conditions and agents used (Lockshin and Zakeri, 2004; Kroemer and Jaattela, 2005; Levine and Yuan, 2005; Amaravadi et al., 2007).

In this study, we describe the use of inducible short hairpin RNAs (shRNAs) to specifically and stably knock down each of the three individual Akt isoforms, both singly and in all possible combinations, in human cancer cells deficient for the tumor suppressor phosphatase and tensin homologue (PTEN), a negative regulator of the PI3K–Akt pathway. This approach avoids the possible nonspecific or side effects associated with systemic treatment of small molecule inhibitors, allowing us to evaluate the specific contributions of the Akt proteins in proliferation, survival, and tumor maintenance both in vitro and in vivo. We show that silencing Akt1 alone can suppress tumor growth, whereas simultaneous knockdown (KD) of all three isoforms provides the most consistent and pronounced tumor growth inhibition. The tumor cells exhibit markedly increased autophagy as a major response to reduced Akt activity, whereas classical apoptosis was not the prevailing response. Blocking lysosome function by a constitutively active Akt is linked to its ability to inhibit autophagy but not apoptosis in a recent study (Degenhardt et al., 2006), raising the possibility that autophagy may also be an important mechanism underlying the response to therapeutic agents targeting the PI3K–Akt pathway. Autophagy is a catabolic process characterized by the appearance of autophagic vacuoles (AVs) in the cytoplasm, leading to self-digestion of cytoplasmic organelles and other constituents in the lysosomal compartments. Although autophagy may be capable of ultimate cell killing when allowed to reach its limit, it is also thought to be a temporary survival mechanism under stress conditions, and inhibiting autophagy can either promote or inhibit cell death depending on the conditions and agents used (Lockshin and Zakeri, 2004; Kroemer and Jaattela, 2005; Levine and Yuan, 2005; Amaravadi et al., 2007).

Results

Inducible shRNA KD of Akt isoforms inhibited the growth of PTEN-null human tumor xenografts in a dose- and isoform-dependent manner

To determine the relative contribution of the three Akt isoforms in maintaining tumor growth, we used a tet-inducible shRNA KD method using a recently described retroviral vector system, pHUSH (a tet-inducible plasmid vector for H1 or U6 short hairpin; Gray et al., 2005; Hoefl ich et al., 2006). We chose the PTEN-null human prostate cancer cell line PC3 and the glioma cell line U87MG (Li et al., 1997). Both lines express all three Akt isoforms; in PC3 cells, Akt1 protein is expressed at approximately two times the level of Akt2, with Akt3 contributing to <10% of total Akt, whereas in U87MG cells, all three Akt proteins are expressed at equivalent levels (Fig. S1 A, available at http://www.jcb.org/cgi/content/full/jcb.200801099/DC1). Stable clones of PC3 and U87MG cells were generated harboring inducible shRNA constructs targeting all possible single and combined Akt isoforms (Table S1). Each Akt-targeting shRNA (shAkt) caused ~75–99% KD of the corresponding Akt mRNA and proteins upon doxycycline (Dox) induction (Fig. 1 A, Fig. S1 B, and Table S2). Decreased steady-state phosphorylation of downstream targets PRAS40 and S6, up-regulation of p27Kip1, and feedback stabilization of IRS1 were observed to varying degrees in response to the KDs, with the strongest effects observed in cells with all three Akt KDs (Fig. 1 A).

We next examined the effect of Akt KDs on the ability of PC3 cells to maintain the growth of established tumors in vivo. Dox-induced KD of Akt2 (shAkt2) or Akt3 (shAkt3) alone did not result in significant inhibition of tumor growth (Fig. 1 B and Table S2). In contrast, two different shRNA constructs targeting Akt1 (shAkt1) both showed significant tumor growth inhibition, each in two out of three independent clones. Tumor growth retardation or stasis was typically observed in these clones (Fig. 1 B, Fig. S1 H, and Table S2). Simultaneous KD of Akt1,2 (shAkt12) or Akt1,3 (shAkt13) also inhibited tumor growth, with almost all tumor growth halted and tumor regression observed in several of the Dox-treated mice. Interestingly, KD of both Akt2 and Akt3 (shAkt23) also resulted in significant tumor growth inhibition, with no tumor volume doubling during the 2 wk of Dox treatment, suggesting that Akt1 activity alone is not sufficient to maintain optimal tumor growth. Finally, triple-Akt KD (shAkt123) most effectively inhibited tumor growth, with consistent tumor regression observed during the first 2 wk of treatment. Similar results were observed in U87MG cells, which express similar levels of the three Akt isoforms. Among the three single KDs, only shAkt1 showed significant tumor stasis, and tumor regression was again observed with triple-Akt KD (Fig. S1 C–F). Thus, KD of Akt1 alone can inhibit tumor growth in both PC3 and U87MG xenografts, and this Akt1 dependency is not simply a total Akt dose effect. More pronounced tumor growth inhibition and regression, however, occurs in tumors with KD of all three Akt isoforms.

Akt KDs induced cell cycle delay without significant apoptosis

Analysis of PC3 tumors with Akt KDs revealed a mild decrease in the proliferation marker Ki-67 and no significant increase in TUNEL-positive cells compared with control tumors (Fig. 2 A). The lack of apoptosis was also observed in PC3 cells cultured in vitro. Under 10% FBS, a mild increase in G0/G1 and a decrease in S phase was observed in cells expressing each shAkt construct. Slightly increased accumulation of cells in the G2/M phase was also observed in cells expressing shRNA for Akt1 alone and any combinations of two or three Akt isoforms, suggesting a cell cycle delay in both DNA replication and mitosis in these cells. However, no significant sub-G1 population was observed with any of the KDs (Fig. S2, A and B, available at http://www.jcb.org/cgi/content/full/jcb.200801099/DC1). Additional experiments also failed to detect significant caspase

Downloaded from on June 21, 2017
activation in response to Akt KDs in both PC3 and U87MG cells (unpublished data). To partially mimic the suboptimal growth condition in the in vivo environment, we starved the cells of serum in culture and asked whether the cells became more sensitive to Akt KD. Indeed, complete serum starvation or reducing serum to 0.5% resulted in markedly increased accumulation of cells in the G0/G1 phase. However, still no significant sub-G1 peak was observed for at least 2 d in 0% FBS and 5 d in 0.5% FBS (Fig. 2, B and C).

Akt KD promoted autophagy in PC3 and U87MG cells

Because Akt has been shown to inhibit autophagy (Arico et al., 2001; Degenhardt et al., 2006), we asked whether specific KD of endogenous Akt could promote autophagy. Indeed, EM analysis revealed a significantly increased accumulation of AVs in both PC3 and U87MG cells induced to express shAkt123 (Fig. 3, A and B; and Fig. S2 C). The accumulation of AV and acidic vesicular organelles (AVOs) was further confirmed by localization of the autophagosome marker GFP-LC3, staining with an anti-LC3 antibody, and fluorescent dyes monodansylcadaverine (MDC) and acridine orange (AO; Fig. 4 A, Fig. S2, D–G, and not depicted).

We examined xenograft tumors expressing shAkt by EM. The control GFP-targeting shRNA–expressing PC3 tumors consist of healthy looking cells connected by cell–cell junctions (Fig. 3 C, a). In contrast, cells in the shAkt123–expressing tumors exhibit morphological signs of degeneration and loss of cell–cell contact after 10–15 d of Dox treatment (Fig. 3 C, b). Late AVs positive for human lysosome-associated membrane protein (LAMP)1 are found in degenerating tumor cells (Fig. 3 C, b–d). Also, these cells often contain swollen mitochondria and dilated RER that are drastically disorganized, suggesting a connection between energy metabolism, ER stress, and autophagy. Chromatin clumping and fragmentation characteristic of typical apoptosis are rarely observed in the degenerating tumor cells; instead, some AV-containing cells exhibit mild pyknosis typical of cells undergoing autophagic degeneration (Fig. 3 C, b and d).

To determine whether AV accumulation occurred in tumor cells before morphological signs of degeneration, we examined U87MG tumors with either 5 d or 3 wk of Akt KD. In tumors expressing shAkt123 for 5 d, most cells showed similar gross morphology to vehicle-treated controls, but with an approximately twofold increase in the percent AV area (from 0.78% in the control tumors to 1.53% in Dox-treated tumors; P < 0.05; Fig. 3 C, e–h). After 3 wk of Akt KD, U87MG tumors show signs of degeneration in many cells similar to PC3 tumors treated for 15 d (unpublished data).

Lysosomotropic agents accelerated cell death in PC3 cells with Akt KD

Despite the elevated levels of autophagy and mild cell cycle delay, PC3 cells expressing shAkt123 can survive in culture for many passages under 10% FBS without appreciable increase in cell death. Even under reduced serum (0.5% FBS), there is only marginal decrease in viability over a prolonged period.
somes (Fig. 4 B; Klionsky et al., 2008). The lysosomotropic agent chloroquine (CQ), a weak base amine widely used to inhibit the maturation of autophagosomes into degradative autolysosomes (Boya et al., 2005; Kroemer and Jaattela, 2005; Lum et al., 2005), caused the appearance of small GFP-LC3 clusters in the perinuclear region. The combination of CQ with Akt KD resulted in a much stronger accumulation of GFP-LC3 dots as well as augmented accumulation of LC3-II in the presence of continued LC3-I turnover, consistent with a defect in autolysosomal degradation. Similar accumulation of MDC+ vacuoles was also observed (Fig. S2 F). This was accompanied by an accelerated cell death in shAkt123-expressing cells treated with CQ under 0.5% and, more pronouncedly, 0% FBS (Fig. 4, C and D).

(unpublished data). Although the literature has been controversial on the effect of early stage autophagy inhibition on cell survival, blocking autophagy at a late stage has been more consistently shown to cause accelerated cell death under autophagy-inducing conditions (Kanzawa et al., 2004; Boya et al., 2005; Gonzalez-Polo et al., 2005; Kroemer and Jaattela, 2005; Yu et al., 2006). Therefore, we investigated the effect of blocking the completion of autophagy initiated by Akt KD on cell viability. In PC3-shAkt123 cells stably expressing GFP-LC3, Akt KD resulted in punctate GFP signals (Fig. 4 A and Fig. S2 E) with a corresponding reduction of the nonlipidated precursor form of the endogenous LC3 (LC3-I) and a slight increase in the lipidated autophagosome-localized LC3-II, which is rapidly turned over in the autolyso-
A second lysosomotropic agent, bafilomycin A1 (Ba), which inhibits the vacuolar proton pump (V-H⁺-ATPase) and prevents the proper acidification of lysosomal compartments (Yamamoto et al., 1998), also promoted cell death in combination with shAkt123. Increased annexin V–positive population and caspase-3,7 activity was observed in cells treated with either CQ or Ba in combination with Akt KD, correlating with an increase in poly-ADP-ribose polymerase (PARP) cleavage in these cells (Fig. 4 B). In contrast, pretreatment with 1 mM 3-MA, an inhibitor of the earliest stage of autophagosome formation, attributed to its inhibition of class III PI3K (Seglen and Gordon, 1982; Petiot et al., 2000), suppressed the cell death–promoting effect of either CQ or Ba on shAkt-expressing cells (Fig. 4, C and D).

This suggests that the accelerated cell death caused by the lysosomotropic inhibitors is dependent on the accumulation of abnormal AVs.
In contrast to the broad-spectrum PI3K inhibitors wortmannin or LY294002, which are equipotent at inhibiting both class I and III PI3Ks and inhibit autophagy because of the latter activity (Petiot et al., 2000; Knight et al., 2006), PI-103 is potent at inducing the accumulation of AVs (Fig. 5, B and C). Similar to Akt KD, combination with CQ accelerated the death of cells treated with PI-103 (Fig. 5 A). The markedly increased LC3-II to LC3-I ratio and the appearance of enlarged vacuoles brightly stained by MDC was observed before the detection of overt cell death (Fig. 5, B and C). As observed with Akt KD, pretreatment with 3-MA reduced both LC3-II to -I ratios and the accumulation of MDC+ vacuoles and slowed down the rate of cell death.

Figure 4. Lysosomotropic agents accelerated cell death in combination with Akt KD. (A) CQ treatment caused accumulation of GFP-LC3 dots in Dox-treated PC3-shAkt123 cells. PC3-shAkt123 cells stably expressing GFP-LC3 were pretreated with or without 1 μg/ml Dox for 6 d and treated with or without 10 μM CQ. GFP fluorescence was imaged after 1 d of CQ treatment. Arrowheads point to representative GFP dots or clumps. Bar, 10 μm. (B) Effect of shAkt123 and 10 μM CQ on LC3 processing, PARP cleavage, and total Akt in PC3-shAkt123 cells treated with or without Dox or CQ. The ratios of LC3-II to LC3-I and cleaved (Cl) to full-length (FL) PARP were quantified from immunoblots of cell lysates made at days 1 and 2 of CQ treatment. Immunoblots of day 2 samples are shown. Molecular masses are indicated in kilodaltons parenthetically next to each protein. Data are representative of three independent experiments. (C) CQ promoted cell death in PC3 cells induced to express shAkt123, whereas 3-MA pretreatment delayed this effect. PC3-shAkt123 cells were preincubated with 1 μg/ml Dox and/or 1 mM 3-MA for 3 d before 10 μM CQ or 2.5 nM Ba was added. Cell viability was determined at days 2, 3, and 4 under 0.5% (C) or 0% (D) FBS after CQ or Ba was added. The percentage of the annexin V–positive PI-negative population was determined at days 2, 3, and 4 under 0.5% FBS. Caspase-3/7 activity was determined at days 2 and 3 under 0% FBS and expressed as relative fluorescence units (RFU, in thousands) normalized to the same number of cells. Error bars represent SD of three independent experiments.

CQ accelerated cell death in combination with PI3K and Akt inhibitors

Recently, a phosphatidylinositol ether lipid analogue that inhibits Akt activation was reported to induce autophagy with radiosensitizing effect (Fujiwara et al., 2007). Because phosphatidylinositol ether lipid analogues are known to have additional cellular targets (Gills et al., 2006; Memmott et al., 2008), we asked whether other specific inhibitors of PI3K–Akt could also induce autophagy and sensitize cells to late stage autophagy inhibition. We first used a dual PI3K/mTOR inhibitor, PI-103, which inhibits the class I PI3Ks and mTOR at nanomolar concentrations but is >1,000-fold less potent on the class III PI3K (Knight et al., 2006). In contrast to the broad-spectrum PI3K inhibitors wortmannin or LY294002, which are equipotent at inhibiting both class I and III PI3Ks and inhibit autophagy because of the latter activity (Petiot et al., 2000; Knight et al., 2006), PI-103 is potent at inducing the accumulation of AVs (Fig. 5, B and C). Similar to Akt KD, combination with CQ accelerated the death of cells treated with PI-103 (Fig. 5 A). The markedly increased LC3-II to LC3-I ratio and the appearance of enlarged vacuoles brightly stained by MDC was observed before the detection of overt cell death (Fig. 5, B and C). As observed with Akt KD, pretreatment with 3-MA reduced both LC3-II to -I ratios and the accumulation of MDC+ vacuoles and slowed down the rate of cell death.
Figure 5. **CQ accelerated cell death in combination with PI-103.** (A) PC3 cells were treated with DMSO or 0.5 μM PI-103 in the presence or absence of 10 μM CQ under 0.5% FBS. Cell viability was determined by PI exclusion at days 2, 3, and 5. Annexin V staining was analyzed at days 2 and 3 and broken down into PI+ or PI− populations. (B) Time course of cell viability in PC3 cells treated with 0.5 (PI-103-0.5) or 20 μM (PI-103-20) PI-103 with or without 10 μM CQ or 3 mM 3-MA. PC3 cells pretreated with PI-103 for 24 h under 1% FBS were split into medium containing 0.5% FBS in the presence or absence of CQ. 3-MA was added immediately before PI-103, 24 h before CQ addition. Cell viability was determined by PI exclusion at the indicated time points after CQ addition. Error bars represent SEM (n = 3). LC3-II to LC3-I ratios were determined from quantitation of immunoblots (with 0.5 μM PI = 103. (C) CQ dramatically increased the size and number of MDC+ vacuoles in PC3 cells treated with PI-103, whereas 3-MA suppressed this effect. Cells were cultured in medium containing 0.5% FBS and treated with DMSO, 0.5 μM PI-103, 10 μM CQ, and 5 mM 3-MA, alone or in combinations as indicated. MDC staining at 48 h is shown. Bar, 10 μm.
Autophagy inhibition and degradation-defective autolysosome accumulation both contribute to accelerated cell death induced by CQ in combination with Akti-1/2

To investigate whether autophagy inhibition by itself is sufficient to induce accelerated cell death in combination with Akt inhibition, we used siRNA to KD Atg7, a gene involved in the formation of autophagosomes (Ohsumi, 2001). KD of Atg7 alone did not show a significant effect on cell death but induced a small drop in cell viability by day 3 when combined with Akti-1/2. However, when combined with both CQ and Akti-1/2, Atg7 KD resulted in a transient delay of cell death at day 2 (Fig. S3, C and D). Together with the aforementioned effect of 3-MA, these data suggest that autophagy inhibition and defective AV accumulation both contribute to the accelerated cell death induced by CQ in combination with Akt inhibition.

Because autophagy is a key function of the lysosomal compartment (Terman et al., 2006), we examined the lysosomal marker LAMP1 and cathepsin D, the predominant lysosomal aspartic protease, by immunoblotting (Fig. 6, B and C). Akti-1/2
alone induced an increase in LAMP1 levels, consistent with an elevated lysosomal activity. Cathepsin D is synthesized as a 43-kD preprocathepsin D that is cleaved cotranslationally and glycosylated to form a 46-kD procathepsin D, which is targeted to lysosomes yielding an intermediate that is further cleaved into a mature enzyme consisting of a 15-kD light chain and a 28-kD heavy chain. Using an antibody that detects both the 28-kD and the precursor forms of cathepsin D, an increase in the level of the premature forms of cathepsin D at 43–50 kD was first detected after Akti treatment alone followed by an increase in the 28-kD heavy chain of the mature enzyme, again indicating an increased lysosomal activity. CQ caused accumulation of the precursor forms at the expense of the 28-kD chain, consistent with an inhibition of lysosomal cysteine protease activity required for the processing and maturation of cathepsin D (Liaudet-Coopman et al., 2006). In cells treated with both Akti and CQ, the precursor forms of cathepsin D accumulated to even higher levels than either alone, whereas the mature 28-kD chain decreased gradually.
Akti treatment also reduced the level of p62, another marker of autophagic activity that is degraded in the autolysosomes (Klionsky et al., 2008), whereas CQ blocked p62 degradation both with and without Akti treatment (Fig. S5 C, available at http://www.jcb.org/cgi/content/full/jcb.200801099/DC1). Collectively, these data suggest that Akt inhibition causes an increased production and maturation of the lysosomal enzymes, whereas CQ treatment impairs the maturation of these enzymes in the final autolysosomal compartment, causing accumulation of defective AVOs. The latter is accompanied by an increased cleavage of caspase 3 into the active forms within 2 d (Fig. 6 B) with a corresponding increase in caspase activity and cleavage of its substrate PARP (unpublished data). zVAD.fmk, a pancaspase inhibitor, partially rescued cell death at all concentrations tested (Fig. S3 E). Although zVAD.fmk can also inhibit lysosomal cysteine proteases at higher concentrations, and the latter have been reported to mediate caspase-independent cell death (Foghgaard et al., 2001), neither of the broad-spectrum cysteine protease inhibitors zFA.fmk and ALLN (N-Acetyl-Leu-Leu-Nle-CHO) nor a more specific cathepsin B inhibitor CA-074-Me showed significant rescue of cell death induced by Akti and CQ. Instead, the cysteine protease inhibitors enhanced cell killing in combination with Akti at 10–50 μM-concentrations, although they also showed cytotoxicity alone at higher concentrations (Fig. S3, F–H). These results suggest that cell death induced by Akti and CQ is at least partially caspase dependent, whereas lysosomal protease activity may be required for the survival of cells under Akt inhibition.

To further ask whether impaired lysosomal degradation can accelerate cell death in combination with Akti inhibition, we knocked down cathepsin D using siRNA. Indeed, this significantly increased cell death when combined with Akti-1/2 and further enhanced the cell-killing effect of CQ when both are combined with Akti (Fig. S3 I). Similarly, pepstatin A, an inhibitor of aspartic proteases including cathepsin D, also promoted cell death together with Akti-1/2 (Fig. S3 J).

**CQ augmented Akti-induced mitochondrial superoxide and cellular reactive oxygen species (ROS) accumulation**

Increasing evidence has suggested an intimate relationship between lysosomes and mitochondria in the execution of programmed cell death (Bursch, 2001; Terman et al., 2006). Therefore, we examined the effect of Akt inhibition and CQ on mitochondrial membrane potential. Consistent with Akt’s function in maintaining mitochondrial integrity (Parcellier et al., 2008), Akti-1/2 alone caused a decrease in mitochondrial membrane potential, although significant numbers of polarized mitochondria were still present in the majority of cells. Although CQ alone did not have a significant effect, cotreatment of CQ and Akti-1/2 caused an almost complete loss of mitochondrial potential, preceding the sharp drop in cell viability (Fig. S4, A and B, available at http://www.jcb.org/cgi/content/full/jcb.200801099/DC1).

It has recently been reported that mitochondrial ROS is involved in autophagy induction (Scherz-Shouval et al., 2007). Because mitochondria are the primary intracellular source of superoxide (O$_2^-$) generation, we analyzed O$_2^-$ production using MitoSOX red, an O$_2^-$ indicator that accumulates in the mitochondria as a function of membrane potential and fluoresces upon oxidation and subsequent binding to DNA. Akti-1/2 alone increased MitoSOX fluorescence within 6 h (Fig. 8 A and C; and not depicted). Most of the fluorescence exhibited a mitochondrial localization pattern with a subpopulation of cells showing
nuclear fluorescence, consistent with increased mitochondrial permeability in these cells. Although CQ alone only caused a mild increase in MitoSOX signal, the combination with Akti-1/2 resulted in a significant increase in fluorescence intensity with most cells exhibiting a strong nuclear staining pattern. The increase in O$_2^-$ production was followed by an increase in overall cellular ROS levels within 24 h, as measured using a general ROS-sensitive probe (Fig. 8, B and C). Interestingly, cytoplasmic ROS signal induced by Akti-1/2 alone was attenuated within 48 h, whereas cotreatment with CQ caused a prolonged increase in ROS levels (Fig. S4 D and not depicted). This is consistent with the notion that limited mitochondrial depolarization caused by Akt inhibition induces a transient ROS signal to increase autophagy, which in turn removes the damaged mitochondria. Impaired digestion of cellular components caused by CQ results in autolysosomal aggregation of deleterious oxidative products such as ceroid/lipofuscin, which can further amplify the ROS damage (Moore et al., 2006), leading to cell death. 3-MA pre-treatment reduced ROS levels induced by Akti (Fig. S4 C), suggesting a class III PI3K dependence similar to starvation-induced ROS production (Scherz-Shouval et al., 2007). Treatment with a general ROS scavenger N-acetylcysteine (NAC) rescued cell viability in the presence of Akti and CQ (Fig. S5, A and B). In addition, NAC reduced Akti-induced LC3 and GFP-LC3 lipidation, p62 degradation, and GFP-LC3 puncta formation (Fig. S5, C and D), consistent with an essential role of ROS in autophagy induction (Scherz-Shouval et al., 2007).

**CQ selectively accelerated cell death in Akti-treated PTEN-null cells in vitro and enhanced the antitumor efficacy of Akt KD in vivo**

Because PC3 cells are PTEN null, we explored whether PTEN status might affect the sensitivity of cells to Akt inhibition alone or in combination with CQ using isogenic PTEN+/+ and PTEN−/− mouse embryonic fibroblasts (MEFs). The PTEN−/− MEFs were previously shown to have elevated Akt pathway activity and are more sensitive to the antiproliferative effect of mTOR inhibition than PTEN+/+ MEFs (Sun et al., 1999). As shown in Fig. 9 A, the PTEN−/− MEFs were also significantly more sensitive to the cell-killing effect of combined CQ and Akti-1/2 than their PTEN+/+ counterparts. This suggests that PTEN−/− cells may be more dependent on autophagic degradation for survival upon Akt inhibition, raising the possibility that a reasonable therapeutic index may be achievable by selective targeting of the malignant PTEN-null tumor cells using this strategy.

To ask whether PTEN-null tumors also rely on autophagic degradation upon Akt inhibition in vivo, we examined the effect of CQ on the survival of PC3 xenograft tumors expressing shAkt123. As shown in Fig. 9 B, intraperitoneal injection of CQ alone caused a small but insignificant reduction in tumor growth rate. Akt KD alone resulted in significant tumor growth inhibition with an initial tumor stasis, but most tumors failed to regress completely, and rebound occurred in 90% of the tumors within 2–3 wk; no complete remission was achieved. In contrast, complete regression was observed in 40% of the tumors treated with both Dox and CQ with stasis maintained in another 20% of the tumors throughout the study (Fig. 9, C and D). Similar results were obtained with a subcutaneous peritumor injection of CQ (unpublished data). EM examination of tumor samples taken at day 5 revealed a mild increase in the AV area in tumors treated with either Dox or CQ alone, whereas a dramatic accumulation of AVs was observed in a tumor treated with both Dox and CQ that showed >50% regression. These AVs are larger than those found in the Dox- or CQ-alone tumors and contain dense undigested materials, but usually with a single-membrane autolysosomal appearance and stained positive for human LAMP1, consistent with impaired degradation after autophagosome–lysosome fusions. This coincides with an increased number of tumor nuclei exhibiting apoptotic morphology as well as AV-containing cell debris with compromised plasma membrane integrity and abnormal mitochondria (Fig. 10 and not depicted). Thus, CQ not only accelerated cell death in combination with Akt inhibition in vitro but also increased the incidence of complete tumor remissions in vivo.

**Discussion**

Using a Dox-inducible shRNA approach, we specifically knocked down each Akt isoform, both individually and in all possible combinations, to evaluate their requirement in the maintenance of tumor growth. Our results suggest that in the PTEN-null PC3 and U87MG cells, Akt1 is the most important isoform, whereas Akt2 and Akt3 activities could partially compensate for the reduced Akt1 activity in maintaining tumor growth. Taking together both the potential metabolic side effects of Akt2 inhibition and the reported increase in invasiveness associated with inhibiting Akt1 alone that could be counteracted by simultaneous inhibition of Akt2 (Irie et al., 2005), it may be necessary to inhibit two or all three Akt isoforms simultaneously to achieve maximum tumor inhibition, but with different degrees of inactivation to preserve crucial levels of isoform activities to reduce side effects.

One of the most prominent functions of Akt is cell survival. Constitutively active Akt has been reported to protect cells from programmed cell death after various proapoptotic insults (Downward, 1998). However, whether apoptosis is a primary response to Akt inhibition is less clear, especially in cancer cells where apoptosis is often suppressed because of various genetic alterations. Previous experiments using small molecule inhibitors of the PI3K–Akt pathway often generate conflicting results that are obscured by their nonspecific effects. Our data indicate that specific KD of Akt can cause cell cycle delay without promoting significant apoptosis. This is consistent with a recent study that only a small portion of total Akt activity is required for apoptosis inhibition (Liu et al., 2006). In contrast, we found that autophagy is a more sensitive response to reduced Akt activity caused by either specific shRNA KD or selective inhibitors of the pathway.

Several mechanisms may contribute to autophagy induction by Akt inhibition. First, inhibiting Akt can lead to mTORC1 inhibition. mTOR is a known inhibitor of autophagy. Interestingly, a constitutively active form of Akt suppressed the induction of autophagy by rapamycin (Takeuchi et al., 2005), raising...
be accelerated through blocking autolysosomal degradation. Although autophagy may be a potential mechanism by which Akt inhibition restricts tumor growth, it may also provide temporary relief from the metabolic and oxidative stress imposed by Akt inhibition. Inhibiting autophagy at an early stage may prevent this temporary protective effect but may also counteract its tumor inhibitory effect while allowing early escape via alternative survival mechanisms. Blocking lysosomal function after tumor cells have become committed and reliant on autophagic degradation, however, might avoid this counteracting effect while amplifying the oxidative damage and cytotoxic effects (Seehafer and Pearce, 2006). Indeed, our data suggest that a compatible lysosomal degradation capacity is critical for cell survival in the presence of elevated autophagic activity induced by Akt inhibition such that inhibiting lysosomal function with lysosomotropic agents, cathepsin D KD or lysosomal protease inhibitors, can all precipitate cell death in combination with Akt inhibition.

the possibility that the effect of rapamycin on autophagy may be mediated at least partially through inhibiting Akt via its long-term effect on mTORC2 (Sarbassov et al., 2006). Second, other signaling outputs of Akt, such as the FoxO proteins (Zhao et al., 2008) or glucose metabolism, can also contribute to autophagy regulation independently of mTOR. Third, our data indicate that Akt inhibition induces increased mitochondrial superoxide and cellular ROS signals that can activate autophagy.

Autophagy activation may lead to eventual cell death when allowed to reach its limit or may sensitize cells to additional death-inducing stimuli either through eventual autophagic cell death or switching to a more rapid death program such as apoptosis. For example, Akt inhibition may increase radiosensitivity through augmenting autophagic response (Fujikawa et al., 2007), whereas calpain-mediated cleavage of Atg5 may switch autophagy into apoptosis (Yousefi et al., 2006). Here we show that inhibiting Akt alone is ineffective in cell killing in the PTEN-null cancer cells that we examined, but cell death can be accelerated through blocking autolysosomal degradation. Although autophagy may be a potential mechanism by which Akt inhibition restricts tumor growth, it may also provide temporary relief from the metabolic and oxidative stress imposed by Akt inhibition. Inhibiting autophagy at an early stage may prevent this temporary protective effect but may also counteract its tumor inhibitory effect while allowing early escape via alternative survival mechanisms. Blocking lysosomal function after tumor cells have become committed and reliant on autophagic degradation, however, might avoid this counteracting effect while amplifying the oxidative damage and cytotoxic effects through accumulation of deleterious oxidative aggregates (Sehafer and Pearce, 2006). Indeed, our data suggest that a compatible lysosomal degradation capacity is critical for cell survival in the presence of elevated autophagic activity induced by Akt inhibition such that inhibiting lysosomal function with lysosomotropic agents, cathepsin D KD or lysosomal protease inhibitors, can all precipitate cell death in combination with Akt inhibition.

Figure 9. CQ selectively accelerated cell death in Akti-treated PTEN-null cells in vitro and enhanced the antitumor efficacy of Akt KD in vivo. (A) PTEN−/− (−/−) MEFs were more sensitive than isogenic PTEN+/− (+/+ ) counterparts to the combined treatment with Akti-1/2 and CQ. MEFs were treated with 5 μM each of Akti-1/2 and CQ under 1% FBS, and cell viability was determined at days 0, 2, and 3 by PI exclusion. Error bars represent SEM (n = 3). (B) Mean tumor volumes of PC3 xenograft tumors treated daily with vehicle (Veh), Dox only, CQ only, or both Dox and CQ over a 28-d period. The vehicle and vehicle + CQ groups were followed for up to 18 d before terminated because of weight loss from the tumor burdens. Error bars represent SEM (n = 10 tumors in each cohort). (C) Scatterplot of the tumor volumes in the Dox only and Dox + CQ groups on day 28 (P = 0.05). Horizontal bars indicate mean tumor volumes. Numbers of tumors with complete remission (CR, dashed line) are indicated for each group. (D) Individual tumor growth plotted as a percentage of tumor volume change compared with day 0 for the Dox only and Dox + CQ cohorts shown in B. Dashed lines indicate 100% change from the starting tumor volumes, i.e., complete tumor regression. Numbers of tumors with smaller (<0% change) or larger (>0% change) than the starting tumor volumes on day 28 are indicated.
The MitoPT Mitochondrial Permeability Transition Detection kit was purchased from Immunochemistry Technologies, LLC.

Inducible shRNA constructs and generation of inducible-shRNA clones
The pHUSH tetracycline-inducible retrovirus gene transfer vector has been described previously (Gray et al., 2005, 2007; Hoeflich et al., 2006). The complementary double-stranded shRNA oligos were inserted into this vector system using a shuttle vector followed by a Gateway recombination reaction (Invitrogen) as previously described (Grunwald et al., 2002). The shRNA sequences used in this study are summarized in Table S1. All constructs were verified by sequencing. Retrovirus infection was performed as described previously (Gray et al., 2005; Hoeflich et al., 2006). For single Akt isoform KDs, cells were infected with one retroviral vector encoding an shRNA construct singly targeting each Akt isoform (constructs 252 or 253 for Akt1, 254 or 255 for Akt2, and 259 or 260 for Akt3), and stable clones were selected using 5 μg/ml puromycin. For dual Akt1 and Akt2 KD, a single shRNA targeting both Akt1 and 2 simultaneously (constructs 256 and 257) was used. Dual Akt2 and 3 (constructs 255 and 261) or triple Akt1, 2, and 3 (constructs 257 and 261) KDs were achieved by coinfecting the cells with two retroviral vectors containing different antibiotic selection markers (puromycin and hygromycin), each encoding one single shRNA, and stable clones were selected using 5 μg/ml puromycin and 300 μg/ml hygromycin. For dual Akt1 and 3 KD, either a single shRNA targeting both Akt1 and 3 (construct 258) or coinfection with two shRNA vectors (constructs 253 and 261) was used.

GFP-LC3 stable transfection
DNA construct containing human LC3B tagged at the N terminus with EGFP was transfected into PC3-shAkt123 and PC3 wild-type cells. Stable clones were selected using G418.

Immunoblot analysis, immunohistochemistry (IHC), and TUNEL assay
For immunoblot analysis, total protein lysates were subjected to SDS-PAGE and transferred to nitrocellulose. Antibodies used were anti-Akt1, anti-total-Akt, anti-phospho-Akt, and anti-tubulin. Immunohistochemistry was performed as previously described (Grunwald et al., 2002). The TUNEL assay was performed as described previously (Gray et al., 2005; Hoeflich et al., 2006). The percentages of apoptotic nuclei among randomly sampled tumor cell nuclei (n = 3–4 sets of 100 tumor cell nuclei) were quantified.

Materials and methods
Cell culture and reagents
The PTEN+/− and PTEN−/− MEFs were maintained as previously described (Sun et al., 1999). The PC3 and U87MG cells were maintained at 37°C and 5% CO2 in DME/Ham’s F-12 (1:1) containing 10% tetracycline-free FBS (Invitrogen). Akti-1/2 was obtained from EMD (Akt inhibitor VIII; Barnett et al., 2005). To inhibit autophagy, cells were treated with 5–10 μM CQ, 2.5 nM Ba, or 1–5 mM 3-MA (all from Sigma-Aldrich) and analyzed at the indicated time points. MitoSOX red mitochondrial superoxide indicator and Image-iT LIVE Green ROS Detection kits were purchased from Invitrogen.
anti-p-Akt (Ser473), anti-p-Akt (Thr308), anti-p-S6 (Ser235/236), anti-PARP, and activated caspase-3 (Cell Signaling Technology); anti-Akt2, anti-Akt3, and anti-IRS1 (Millipore); anti-p-PRAS40 and anti-GFP (Invitrogen); anti-p27Kip1 (Santa Cruz Biotechnology, Inc.); anti-LC3 (Novus); anti-LAMP2 and anti-cathepsin D (BD Biosciences); anti-p62/SQSTM1 (BIMOC International, LP); anti-β-actin (Sigma-Aldrich); and anti-glyceraldehyde-3-phosphate dehydrogenase (Advanced Immunotechnical Inc.). Primary antibodies were detected using IR Dye 800-conjugated (Rockland) and Alexa Fluor 680-conjugated (Invitrogen) species-selective secondary antibodies. Detection and quantification were performed using an infrared scanner (Odyssey; LI-COR) using the manufacturer’s software. For IHC, formalin-fixed, paraffin-embedded sections were collected. 5-μm-thick paraffin-embedded sections were stained using an anti-Ki67 (MIB-1; Dako) antibody with the Animal Research Kit (Dako). Tissues were counterstained with hematoxylin, dehydrated, and mounted. In all cases, antigen retrieval was performed with the Target Retrieval Kit (Dako) according to the manufacturer’s instructions. For TUNEL assay, formalin-fixed, paraffin-embedded sections were stained using an in situ cell death detection kit (POD; Roche) according to the manufacturer’s instructions.

**Xenograft study**

6–8-wk-old female athymic nude nu/nu mice were purchased from Charles River Laboratories and maintained in Genentech’s conventional animal facility. Mice were injected in the right flank with 5–7.5 × 10⁶ cells suspended in 200 μl Hank’s balanced salt solution (Invitrogen). When tumors reached a mean volume of 100–300 mm³, the mice with similarly sized tumors were grouped into treatment cohorts. Mice received 5% sucrose or 5% sucrose plus 1 mg/ml Dox in drinking water for control and KD cohorts, respectively. Amber-colored water bottles were used and were changed three times per week. CQ was dissolved in 0.9% physiological saline, filter sterilized, and administered at 45 mg/kg through either intraperitoneal or subcutaneous routes. Tumors were measured with calipers, and cohorts were weighed twice per week. Mice whose tumors reached 2,000 mm³ or lost >20% body weight were killed. Between 8 and 10 mice were used for each treatment group. Statistical significance was analyzed using JMP software (SAS Institute, Inc.).

**Fluorescence microscopy**

For LC3 immunofluorescence staining, cells were fixed in 3% paraformaldehyde and permeabilized with 0.01% digitonin in PBS followed by a rabbit polyclonal anti-LC3 (Abgent) primary antibody detected with a cy3-conjugated anti-rabbit secondary antibody (Jackson Immunotechnology, Inc.). Cells were imaged by using a deconvolution microscopy system (DeltaVision; Applied Precision, LLC) built on an inverted microscope (IX-70; Olympus) with a Plan Apo 60 × /1.40 numerical microscopy system (DeltaVision; Applied Precision, LLC) built on an inverted microscope (IX-70; Olympus) with a Plan Apo 60 × /1.40 numerical microscopy system (DeltaVision; Applied Precision, LLC).

**EM**

Cells were grown to monolayer in plastic flasks and fixed in 4% paraformaldehyde and 0.2% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4, for 5 h at 4°C. After rinsing with PBS, the blocks were embedded in 12% gelatin, cryoprotected with 2.3 M sucrose, and frozen in liquid nitrogen. Ultrathin cryosections were cut at −120°C, picked up with 1% methylcellulose and 1.2 M sucrose, thawed, and collected on copper grids. After washing with PBS containing 0.02 M glycine, sections were incubated with rabbit anti-human LAMP1 antibodies (provided by M. Fukuda, Burnham Institute for Medical Research, La Jolla, CA; Carlson et al., 1998) or with rat monoclonal antibody to mouse LAMP1 (clone 1D3; Babco) (provided by T. August, Developmental Studies Hybridoma Bank, Iowa City, IA) followed by a secondary antibody anti–rat IgG antibody (Dako). The sections were subsequently incubated with protein A conjugated to 10-nm colloidal gold particles and contrasted with a 1.8% methylcellulose and 0.6% uranyl acetate mixture.

**Cell viability and cell cycle analysis**

Cell number and viability were measured using trypan blue exclusion assay using a Vi-Cell Analyzer (Beckman Coulter) or labeled with 1 μg/ml Propidium iodide (PI) in PBS/1% BSA followed by cytofluorometric analysis with a fluorescence-activated cell sorter (Becton Dickinson). FITC-conjugated annexin V was used for the assessment of phosphatidylserine exposure by fluorescence-activated cell sorter analysis. Caspase activation was analyzed using a Caspase-Glo 3/7 Assay Kit (Promega). For cell cycle analysis, cells were fixed with dropwise addition of chilled 70% ethanol, washed with PBS, and resuspended in solution containing 50 μg/ml PI and 60 U RNase A. DNA content was analyzed by flow cytometry using the FlowJo and ModFit software (Becton Dickinson).

**Multispectral imaging flow cytometry**

Cells treated with various agents were stained with 1 μg/ml AO and analyzed by the ImageStream system (Amnis Corporation) using the IDEAS image analysis program. This allows quantitative characterization of single cells within a population by assessing a combination of morphology and fluorescence patterns. AO fluoresces green when bound to nuclei and red when concentrated in acidic vacuoles. The DNA AO green image and the vacuolar AO red image were first compensated into separate channels, and the percentage of apoptotic/anucleate cells (based on AO nuclear morphology and intensity) and vacuolated cells (AO red+) were quantified. Plotting AO green intensity versus the AO green bright detail area revealed three distinct populations: R2 anucleated cells (low AO green labeling and higher area caused by masking of diffuse cytoplasm), R3 apoptotic cells (intermediate to low AO green and very low AO green detail area caused by the presence of small, bright condensed nuclear fragments), and R4 live cells (intact bright nuclei). AO red intensity is plotted on the second histogram, with an arbitrary gate (RS) drawn to include events with the brightest AO red intensity.

**Time-lapse video microscopy**

Cells cultured in 24- or 96-well plates were imaged on an inverted microscope (IX81; Olympus; or TE300; Nikon) equipped with environmental microscopy (ix70/Olympus) with a Plan Apo 60 × /1.40 numerical aperture. Single-band excitation and emission filters, a high-resolution cooled charge-coupled device (CCD) camera (CH350; Roper Scientific), and SOFTWORX software (version 2.5; Applied Precision, LLC). For labeling of AVs with MDC, cells were incubated with 0.05 mM MDC in PBS at 37°C for 10 min and immediately analyzed by fluorescence microscopy using an inverted microscope (Eclipse TE 300; Nikon) equipped with a CCD camera (SPOT; Diagnostic Instruments, Inc.).

**Online supplemental material**

Table S1 shows a summary of Akt shRNA oligos and constructs. Table S2 shows a summary of Akt KD efficiency and effect on xenograft tumor growth for various PC3-Akt shRNA clones. Fig. S1 shows relative levels of Akt isoforms in cancer cell lines and inducible KD of Akt isoforms in U87MG cells and xenograft tumors. Fig. S2 shows the effect of GFP-targeting shRNA and Akt isoform KDs on cell cycle progression, apoptosis, and autophagy. Fig. S3 shows the effect of LAMP2, Atg7, protease inhibitors, cathepsin D siRNA, and pepstatin A on PC3 cell viability in combination with PI-103 or Akti-1/2. Fig. S4 shows CQ-promoted mitochondrial membrane depolarization and cellular ROS accumulation in combination with Akti-1/2. Fig. S5 shows NAC-rescued cell death induced by Akti + CQ. Video 1 is a time-lapse video of PC3 cells treated with DMSO control. Video 2 is a time-lapse video of PC3 cells treated with CQ alone. Video 3 is a time-lapse video of PC3 cells treated with Akti-1/2 alone. Video 4 is a time-lapse video of PC3 cells treated with both CQ and Akti-1/2. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200801099/DC1.

References


Kroemer, G., and M. Jaattela. 2005. Lysosomes and autophagy in cell death con-


Table S1. **Summary of Akt shRNA oligos and constructs**

<table>
<thead>
<tr>
<th>Target</th>
<th>Construct #</th>
<th>Selection</th>
<th>Target sequence*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akt1</td>
<td>252</td>
<td>Pur</td>
<td>5'-TGACCATGAACGAGTTTGA-3'</td>
</tr>
<tr>
<td>Akt1</td>
<td>253</td>
<td>Pur</td>
<td>5'-GTGGACCACGTGATCGAA-3'</td>
</tr>
<tr>
<td>Akt2</td>
<td>254</td>
<td>Pur</td>
<td>5'-CCTGGAGGCCACGGTACTT-3'</td>
</tr>
<tr>
<td>Akt2</td>
<td>255</td>
<td>Pur</td>
<td>5'-TGACTTCGACTATCTCAAA-3'</td>
</tr>
<tr>
<td>Akt3</td>
<td>259</td>
<td>Pur</td>
<td>5'-GAATTGTAGTCCAACCTTCA-3'</td>
</tr>
<tr>
<td>Akt3</td>
<td>260</td>
<td>Pur</td>
<td>5'-GCACCTTGGGAAGTTAT-3'</td>
</tr>
<tr>
<td>Akt3</td>
<td>261</td>
<td>Hyg</td>
<td>5'-GCACCTTGGGAAGTTAT-3'</td>
</tr>
<tr>
<td>Akt12</td>
<td>256</td>
<td>Pur</td>
<td>5'-GCTACTACGCCATGAAGAT-3'</td>
</tr>
<tr>
<td>Akt12</td>
<td>257</td>
<td>Pur</td>
<td>5'-AGGTGCCTGGAGGACATGA-3'</td>
</tr>
<tr>
<td>Akt13</td>
<td>258</td>
<td>Pur</td>
<td>5'-CTACAACCAGGACCATGAG-3'</td>
</tr>
<tr>
<td>Akt13</td>
<td>253 + 261</td>
<td>Pur + Hyg</td>
<td>253 and 261 target sequences</td>
</tr>
<tr>
<td>Akt23</td>
<td>255 + 261</td>
<td>Pur + Hyg</td>
<td>255 and 261 target sequences</td>
</tr>
<tr>
<td>Akt123</td>
<td>257 + 261</td>
<td>Pur + Hyg</td>
<td>257 and 261 target sequences</td>
</tr>
</tbody>
</table>

Hyg, hygromycin; Pur, puromycin.

*Sense sequence in the target.
Table S2. Summary of Akt KD efficiency and effect on xenograft tumor growth for various PC3-Akt shRNA clones

<table>
<thead>
<tr>
<th>Target/construct</th>
<th>Clone</th>
<th>Treatment</th>
<th>% Akt1−</th>
<th>% Akt2−</th>
<th>% Akt3−</th>
<th>p−</th>
<th>R−</th>
<th>% TGI (d14)−</th>
<th>DR5−</th>
<th>% TGI (DRS)−</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akt1</td>
<td>252</td>
<td>Dox−</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>8</td>
<td>6</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>252</td>
<td>Dox+</td>
<td>21.9 ± 1.1</td>
<td>93.8 ± 10.2</td>
<td>151 ± 58.3</td>
<td>8</td>
<td>8</td>
<td>−14 &gt;21</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>252</td>
<td>Dox−</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>8</td>
<td>5</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>252</td>
<td>Dox+</td>
<td>22.3 ± 2.3</td>
<td>122.7 ± 11.3</td>
<td>120.3 ± 8.6</td>
<td>8</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>252</td>
<td>Dox−</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>8</td>
<td>8</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>252</td>
<td>Dox+</td>
<td>11.6 ± 2.6</td>
<td>89.1 ± 13.9</td>
<td>106.8 ± 3.2</td>
<td>8</td>
<td>5</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>252</td>
<td>Dox−</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>8</td>
<td>7</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>252</td>
<td>Dox+</td>
<td>11.6 ± 2.6</td>
<td>80.1 ± 9.7</td>
<td>106.1 ± 4.3</td>
<td>8</td>
<td>2</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>252</td>
<td>Dox−</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>8</td>
<td>7</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>252</td>
<td>Dox+</td>
<td>13.9 ± 5</td>
<td>82.3 ± 1.3</td>
<td>92.9 ± 5.3</td>
<td>8</td>
<td>7</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>252</td>
<td>Dox−</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>10</td>
<td>10</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>252</td>
<td>Dox+</td>
<td>5.9 ± 0.1</td>
<td>70.3 ± 5.6</td>
<td>98 ± 1</td>
<td>10</td>
<td>8</td>
<td>0</td>
<td>56±</td>
<td>5</td>
</tr>
<tr>
<td>Akt2</td>
<td>255</td>
<td>Dox−</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>8</td>
<td>7</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>255</td>
<td>Dox+</td>
<td>88 ± 16.5</td>
<td>11.6 ± 2.4</td>
<td>116.4 ± 32</td>
<td>8</td>
<td>5</td>
<td>2</td>
<td>−7 &gt;21</td>
<td></td>
</tr>
<tr>
<td>Akt3</td>
<td>260</td>
<td>Dox−</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>10</td>
<td>10</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>260</td>
<td>Dox+</td>
<td>105 ± 6.1</td>
<td>10.4 ± 1.3</td>
<td>106.3 ± 8</td>
<td>10</td>
<td>9</td>
<td>0</td>
<td>22 &gt;21</td>
<td></td>
</tr>
<tr>
<td>Akt12</td>
<td>257</td>
<td>Dox−</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>8</td>
<td>3</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>257</td>
<td>Dox+</td>
<td>5.7 ± 0.9</td>
<td>13.2 ± 1.1</td>
<td>129.6 ± 11.3</td>
<td>8</td>
<td>0</td>
<td>5</td>
<td>137±</td>
<td>14</td>
</tr>
<tr>
<td>Akt13</td>
<td>253 + 261</td>
<td>Dox−</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>8</td>
<td>8</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>253 + 261</td>
<td>Dox+</td>
<td>5.1 ± 2.0</td>
<td>6.6 ± 2.6</td>
<td>18 ± 3.7</td>
<td>8</td>
<td>1</td>
<td>3</td>
<td>102±</td>
<td>7</td>
</tr>
<tr>
<td>Akt23</td>
<td>255 + 261</td>
<td>Dox−</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>8</td>
<td>6</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>255 + 261</td>
<td>Dox+</td>
<td>96.8 ± 18.8</td>
<td>6.3 ± 0.3</td>
<td>9.9 ± 2.1</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>82±</td>
<td>7</td>
</tr>
<tr>
<td>Akt123</td>
<td>257 + 261</td>
<td>Dox−</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>8</td>
<td>8</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>257 + 261</td>
<td>Dox+</td>
<td>1.2 ± 0.3</td>
<td>9.5 ± 0.7</td>
<td>4.5 ± 2.1</td>
<td>10</td>
<td>0</td>
<td>6</td>
<td>116±</td>
<td>6</td>
</tr>
<tr>
<td>EGFP</td>
<td>310</td>
<td>Dox−</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>10</td>
<td>8</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>310</td>
<td>Dox+</td>
<td>9 ± 3.6</td>
<td>21.7 ± 2.9</td>
<td>12.7 ± 0.9</td>
<td>8</td>
<td>0</td>
<td>5</td>
<td>116±</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>310</td>
<td>Dox−</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>10</td>
<td>5</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>310</td>
<td>Dox+</td>
<td>9 ± 3.6</td>
<td>21.7 ± 2.9</td>
<td>12.7 ± 0.9</td>
<td>10</td>
<td>1</td>
<td>4</td>
<td>106±</td>
<td>10</td>
</tr>
</tbody>
</table>

TGI, tumor growth inhibition; DRS, days to reach significance.

- Percentage of message level after 72 h of Dox treatment compared with untreated control determined by real-time quantitative RT-PCR (Taqman). Data represent mean ± SEM of at least three independent experiments.
- Number of tumors analyzed in each cohort.
- Number of tumors progressed by day 14, defined by tumor volume more than twofold of the initial size at the start of treatment.
- Number of tumors regressed by day 14, defined by tumor volume <50% of the initial size at the start of treatment.
- Percentage of tumor growth inhibition at day 14 or the first day when significant difference was achieved, calculated as % TGI = (% Vc(dx − d0) − Vt(dx − d0))/Vc(dx − d0) × 100, in which Vc(dx − d0) is the difference in mean tumor volume of the control cohort (Vc) between the day of analysis (dx) and the day when treatment started (d0), and Vt(dx − d0) is the difference in mean tumor volume of the treated cohort (Vt) between the day of analysis and the day when treatment started. % TGI >100 indicates tumor regression.
- The number of days taken after treatment before significant difference between the control and the treatment group is achieved.

<0.05 compared with the sucrose vehicle-treated group, determined by Student’s t-test.